A pooled MADRS/IDS cross-correlation analysis: Clinician and patient self-report assessment of improvement in core depressive symptoms with adjunctive aripiprazole

Journal of Clinical Psychopharmacology

Volumn 30, Issue 3, 2010, Pages 300-305

  Reimherr, Frederick W ^a   Martin, Michael L ^b   Eudicone, James M ^b   Marchant, Barrie K ^a   Tran, Quynh Van ^c   Pikalov, Andrei ^c   Marcus, Ronald N ^b   Berman, Robert M ^b   Carlson, Berit X ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Antipsychotic; Atypical; Combination; Depression

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; PLACEBO;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EFFECT SIZE; HUMAN; INTERPERSONAL STRESS; IRRITABILITY; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PHYSICIAN'S ROLE; PIPERAZINES; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952408038     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181db320f     Document Type: Article

References (40)

1. Williams DR, Gonzalez HM, Neighbors H, et al. Prevalence and distribution of major depressive disorder in African Americans, Caribbean blacks, and non-Hispanic whites: results from the National Survey of American Life. Arch Gen Psychiatry. 2007;64(3):305-315.
2. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-3105.
3. Murray CJ, Lopez AD. Evidence-based health policyYlessons from the Global Burden of Disease Study. Science. 1996;274(5288):740-743.
4. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349(9064):1498- 1504.
5. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649-659.
6. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
7. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11): 1905-1917.
8. Rush AJ. STAR*D: what have we learned? Am J Psychiatry. 2007;164(2):201-204.
9. Nierenberg AA, Papakostas GI, Petersen T, et al. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol. 2003;23(1):92-95.
10. Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry. 2003;64(4):403-407.
11. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1519-1530; quiz 1665.
12. Patkar AA, Masand PS, Pae CU, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol. 2006;26(6):653-656.
13. Fava M, Thase ME, DeBattista C, et al. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry. 2007;19(3):153-159.
14. Landen M, Bjorling G, Agren H, et al. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry. 1998;59(12):664-668.
15. Moreno FA, Gelenberg AJ, Bachar K, et al. Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry. 1997; 58(10):437-439.
16. Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry. 2007;68(7):1056-1061.
17. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002;51(2):183-188.
18. DeBattista C, Solvason HB, Poirier J, et al. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. J Clin Psychopharmacol. 2003;23(1):27-30.
19. Ferreri M, Lavergne F, Berlin I, et al. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand. 2001;103(1):66-72.
20. Papakostas GI, Shelton RC, Smith J, et al. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007;68(6):826-831.
21. Dodd S, Berk M. Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility. Expert Rev Neurother. 2008;8(9):1299-1306.
22. Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med. 2007;147(9):593-602.
23. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-853.
24. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156-165.
25. Berman R, Fava M, Thase M, et al. Aripiprazole augmentation in major depression: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectrums. 2009;14(4):197-206.
26. Bech P, Tanghoj P, Andersen HF, et al. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology (Berl). 2002;163(1):20-25.
27. Lecrubier Y, Dolberg OT, Andersen HF, et al. Qualitative changes in symptomatology as an effect of treatment with escitalopram in generalized anxiety disorder and major depressive disorder. Eur Arch Psychiatry Clin Neurosci. 2008;258(3):171-178.
28. Robinson DS, Gilmor ML, Yang Y, et al. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials. Psychopharmacol Bull. 2007;40(3):15-28.
29. Dorée JP, Des Rosiers J, Lew V, et al. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin. 2007;23(2):333-341.
30. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Erlbaum; 1988.
31. Reimherr FW, Martin ML, Qi Y, et al. Adjunctive aripiprazole improves core depressive symptoms: a pooled analysis of Montgomery-Asberg Depression rating Scale items (CN138-139/-163). Presented at the American Psychiatric Association 161st Annual Meeting, May 3-8, 2008, Washington DC, USA 2008.
32. Corruble E, Legrand JM, Zvenigorowski H, et al. Concordance between self-report and clinician's assessment of depression. J Psychiatr Res. 1999;33(5):457-465.
33. Bailey J, Coppen A. A comparison between the Hamilton Rating Scale and the Beck Inventory in the measurement of depression. Br J Psychiatry. 1976;128:486-489.
34. Rush AJ, Hiser W, Giles DE. A comparison of self-reported versus clinician-related symptoms in depression. J Clin Psychiatry. 1987;48(6):246-248.
35. Tondo L, Burrai C, Scamonatti L, et al. Comparison between clinician-rated and self-reported depressive symptoms in Italian psychiatric patients. Neuropsychobiology. 1988;19(1):1-5.
36. Domken M, Scott J, Kelly P. What factors predict discrepancies between self and observer ratings of depression? J Affect Disord. 1994;31(4):253-259.
37. Corruble E, Legrand JM, Duret C, et al. IDS-C and IDS-SR: psychometric properties in depressed in-patients. J Affect Disord. 1999;56(2-3):95-101.
38. Rush AJ, Trivedi MH, Carmody TJ, et al. Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients. Neuropsychopharmacology. 2005;30(2):405-416.
39. Carmody TJ, Rush AJ, Bernstein IH, et al. Making clinicians lives easier: guidance on use of the QIDS self-report in place of the MADRS. J Affect Disord. 2006;95(1-3):115-118.
40. Rush AJ, Carmody TJ, Ibrahim HM, et al. Comparison of self-report and clinician ratings on two inventories of depressive symptomatology. Psychiatr Serv. 2006;57(6):829-837.